Halozyme Therapeutics, Inc. (HALO)

38,64 +0,83 (+2,20%) Alla chiusura: 04:00PM EDT

Halozyme Therapeutics, Inc.

12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889
https://halozyme.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 373

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director	1,82M	5,69M	1963
Ms. Nicole LaBrosse	Senior VP & CFO	849,36k	N/D	1983
Dr. Michael J. LaBarre Ph.D.	Senior VP & Chief Technical Officer	843,89k	2,6M	1964
Mr. Mark Snyder Esq.	Senior VP & Chief Legal Officer	912,87k	N/D	N/D
Ms. Cortney Caudill M.B.A.	Chief Operations Officer	N/D	N/D	N/D
Ms. Tram Bui	Head of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Amy Marinne Fox	Senior Vice President of Human Resources	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Halozyme Therapeutics, Inc. al 1 aprile 2024 è 1. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 1; diritti degli azionisti: 3; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.